Research programme: autoimmune disorders - Abbott Laboratories
Latest Information Update: 23 Jan 2013
At a glance
- Originator Abbott Laboratories; PDL BioPharma
- Developer Abbott Laboratories
- Mechanism of Action Interleukin 12 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Autoimmune disorders